Health

Type 2 Diabetes Pill Cuts Risk of Death, Study Finds

This product image provided by Boehringer Ingelheim Pharmaceuticals shows bottles of Jardiance, a daily pill for Type 2 diabetes. (Boehringer Ingelheim Pharmaceuticals via AP)
This product image provided by Boehringer Ingelheim Pharmaceuticals shows bottles of Jardiance, a daily pill for Type 2 diabetes. (Boehringer Ingelheim Pharmaceuticals via AP)

(CBS News) – The diabetes drug Jardiance sharply reduced chances of dying in diabetic patients at high risk of heart complications, a study shows, making the type 2 diabetes medication the first shown to lengthen diabetics’ lives.

The study found Jardiance reduced deaths from heart complications by 38 percent, deaths from any cause by 32 percent and hospitalizations due to chronic heart failure by 35 percent.

Heart complications prematurely kill many of the estimated 387 million diabetics worldwide, so doctors in recent years have moved from trying to reduce patients’ blood sugar to trying to prevent cardiovascular complications.

The results were particularly striking because nearly four-fifths of the participants were already taking standard medicines to control blood sugar, blood pressure and cholesterol, plus taking either Jardiance or a dummy pill.

READ MORE

Tags
Show More

Related Articles

Leave a Reply

Your email address will not be published. Required fields are marked *


By submitting this form, you are consenting to receive marketing emails from: Washington Informer Newspaper, 3117 Martin Luther King Jr. Ave SE, Washington, DC, 20032, http://www.washingtoninformer.com. You can revoke your consent to receive emails at any time by using the SafeUnsubscribe® link, found at the bottom of every email. Emails are serviced by Constant Contact

Back to top button

My News Matters to me - Washington Informer Donations

Be a Part of The Washington Informer Legacy

A donation of your choice empowers our journalists to continue the work to better inform, educate and empower you through technology and resources that you use.

Click Here Today to Support Black Press and be a part of the Legacy!

Subscribe today for free and be the first to have news and information delivered directly to your inbox.

Select list(s) to subscribe to


By submitting this form, you are consenting to receive marketing emails from: Washington Informer Newspaper, 3117 Martin Luther King Jr. Ave SE, Washington, DC, 20032, http://www.washingtoninformer.com. You can revoke your consent to receive emails at any time by using the SafeUnsubscribe® link, found at the bottom of every email. Emails are serviced by Constant Contact
Close

Adblock Detected

Please consider supporting us by disabling your ad blocker